Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice.
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Main Text:
Resistance against chemotherapy remains a major obstacle in treating patients with acute myeloid leukemia (AML).(1) Novel therapeutic concepts are especially desired to target and eliminate resistant AML stem cells. Here we show that AML stem cells harbor plasticity, a changing pattern of biological behaviour, by demonstrating that AML stem cells reversibly switch from a low-cycling, chemotherapy resistant state into an actively proliferating state associated with response to standard chemotherapy.
We used patient-derived xenograft (PDX) cells from patients with high risk or relapsed AML that were lentivirally transduced for marker expression. We stained these cells with the proliferation-sensitive dye Carboxyfluorescein succinimidyl ester (CFSE), and re-transplanted them into next-recipient mice. A rare subpopulation of AML cells displayed reduced proliferation in vivo, associated with resistance against standard chemotherapy. The proportion of AML cells with stem cell potential was identical in both, the high and low proliferative sub-fractions. In re-transplantation experiments, proliferation behavior proved reversible, and AML stem cells were able to switch between a high and low proliferation state. Our data indicate that AML stem cells display functional plasticity in vivo, which might be exploited for therapeutic purposes, to prevent AML relapse and ultimately improve the prognosis of patients with AML.
AML patients are at risk to suffer disease relapse associated with dismal prognosis.
The rare subpopulation of AML stem cells (or LIC for leukemia initiating cells) might be responsible for relapse by combining self-renewal capacity with dormancy and resistance against standard chemotherapy.(2) AML LIC features, i.e. growth phenotype have long been considered mainly constant and persistent (2) (3) (4) (5) ; in contrast, recent data suggest unsteady features under therapeutic pressure (6, 7) , while data without experimental treatment pressure remain elusive. Putative functional plasticity of AML LIC is of major clinical importance as it might enable novel therapeutic options.
We previously reported functional plasticity in acute lymphoblastic leukemia (ALL), where we showed in vivo that long-term dormant, treatment-resistant ALL cells were able to convert into highly proliferative, treatment-sensitive cells and vice versa (8) .
Nevertheless, AML and ALL differ widely regarding stem cell biology and a defined stem cell hierarchy -characteristic for AML -was never proven in ALL. Based on diverse stem cell characteristics, we considered functional plasticity of LIC conceivable in ALL, but hypothesized its absence in AML.
To test our hypothesis, we studied cells from ten patients with high-risk or relapsed AML of different karyotypes, genotypes and clinical histories (Table S1 ). As a clinicclose model system, primary cells were transplanted into immunocompromised mice, and AML patient-derived xenograft (PDX) models were established.(9) PDX models were selected to allow for serial transplantation; as this ability is restricted to highly aggressive disease, our study is biased towards high risk AML. AML PDX models were genetically engineered to express luciferase for bioluminescence in vivo imaging and mCherry for cell enrichment by flow cytometry. Marker expression remained stable over serial re-transplantation and allowed enrichment of minute numbers of PDX AML cells from murine bone marrow ( Figure 1A , detailed in supplemental methods). As controls, three samples (AML-356, AML-358 and AML-538) were studied without prior genetic engineering.
AML PDX samples showed more than three-fold differences in doubling times in vivo, resulting in variable time to overt disease in mice ( Figure S1AB ). When PDX cells were re-isolated from murine bone marrow, mCherry expression enabled unbiased enrichment of AML PDX cells, independent of other, putatively subpopulationrestricted, surface markers on AML cells ( Figure 1B ). (8, 10) Re-isolation of PDX cells revealed that homing was heterogeneous between samples, as 0.01 to 1% of PDX cells could be re-isolated from mice early after transplantation ( Figure S1C ). The frequency of LIC, as determined in limiting dilution transplantation assays, varied by a factor of 10 between samples ( Figure S1D , Table S2 ). Thus, our AML PDX cohort of aggressive samples displayed major functional inter-sample heterogeneity in vivo, reflecting the known phenotypic heterogeneity of AML. (11) To track in vivo proliferation of AML cells from individual samples, PDX cells were stained with CFSE, a dye that is not metabolized in eukaryotic cells, but decreases upon cell divisions, indicating proliferation.(12) CFSE records a cell's proliferative history rather than providing a snapshot of the cell´s proliferative state at a given 3 moment. CFSE content was measured by flow cytometry at different time points following injection into groups of mice.
In accordance with an increase in leukemic burden and numbers of re-isolated cells S2A ). We called these cells label-retaining cells (LRC) according to literature (8) .
LRC were found in 9/10 samples tested ( Figures 1EF and S2AB) . Only a single sample originating from child with fatal AML relapse had entirely lost the LRC population between day 7 to 15 ( Figure S2C ), again highlighting the known heterogeneity of AML.(11) Cell cycle analysis confirmed that LRC divide less as compared to non-LRC ( Figure S3A ). Together, our data reveal, in the majority of cases, heterogeneity of in vivo growth behavior within individual AML PDX samples, including a subpopulation of low-cycling LRC. Hence, our results add an important level of phenotypic heterogeneity to AML on top of the known heterogeneity of e.g. immunophenotypes, or gene expression profiles. As a large range of AML subtypes were studied (Table S1) , the novel characteristic is not limited to a specific cytogenetic or genetic subgroup.
To further characterize attributes of LRC, gene expression analysis of 24 LRC and non-LRC samples isolated from AML-393 and AML-491 was performed.(13) Among the top down regulated gene sets in LRC were cell cycle regulators, confirming the reduced proliferative state of these cells ( Figure S3BC ); among the top upregulated gene sets were cell adhesion molecules ( Figure S3C ). Notably, LRC of AML-393 were more similar to LRC of AML-491 than to their own non-LRCs ( Figure 1G ), despite the substantial differences in the mutational profile of AML-393 and AML-491 (Table S1 ). Even more striking, gene-set enrichment analysis identified a high overlap of significantly deregulated genes between AML LRC and our previously defined LRC signature in ALL (8) ( Figure 1H and S3C), suggesting comparable biologic processes activated in LRC of both, AML and ALL.
Given the long-known link between dormancy and chemo-resistance (14) , we compared drug response between low-cycling LRC and high-cycling non-LRC.
Groups of mice engrafted with CFSE-labeled cells were treated with a chemotherapeutic regimen mimicking "7+3" induction therapy(1), consisting of cytarabine and liposomal daunorubicin (DaunoXome) (Figure 2A ). In vivo treatment diminished tumor burden as monitored by in vivo imaging ( Figure 2B ), resulting in a decrease of total isolated PDX cells by at least one order of magnitude ( Figure 2C ). Table S3 ), and no difference in CD34 + CD38cells between the two groups ( Figure S5 ), strengthening previous findings. (15) Notably, CD34 + CD38cells were barely detectable in the aggressive AML-393 sample, despite high LIC frequency ( Figure S5 , Table S2 ). These data indicate that LIC reside not only in the low-cycling LRC, but also in the high-cycling non-LRC compartment, indicating heterogeneity in proliferation dynamics within the AML LIC pool.
As low-cycling cells were able to convert to active proliferation, we asked whether the switch could also occur vice versa. To test whether LRC could be replenished from non-LRC, we re-transplanted high cell numbers of non-LRC restained with CFSE ( Figure 3D Taken together, our data shows that low proliferation or dormancy characterizes a temporary, reversible cell state rather than a defined subpopulation of cells. AML contains a rare fraction of low-cycling, chemo-resistant LIC which are functionally plastic; AML LIC might temporarily adopt a low-cycling LRC phenotype or switch to a rapidly proliferating non-LRC phenotype, triggered by external stimuli such as retransplantation. Even the highly aggressive AML samples used in this study harbor the potential to adopt a proliferative phenotype associated with response to standard chemotherapy.
Unexpectedly, we detected similar functional plasticity in AML as previously observed in ALL (8) . This was accompanied by similar changes in gene expression profiles, although both diseases differ substantially regarding their stem cell biology as ALL never revealed a stem cell hierarchy as proven in AML. In contrast to ALL, AML plasticity comes as a major surprise, as we show here that high-cycling cells harbor the potential to convert into low-cycling cells, while both populations retain stem cell capacities. In our experiments, neither functionally nor immunophenotypically defined LIC were enriched in the LRC fraction, suggesting that dormancy and stemness are not consistently linked in AML, but that dormancy characterizes a temporary cell state rather than a defined subpopulation of cells. In addition to the known constant, presumably deterministic factors defining stemness, AML stem cells appear to be regulated by additional, transient and putatively stochastic factors. (16) Our data indicates that stemness and resistance to anti-leukemic therapy is not strictly linked in AML. This opens exciting therapeutic potential to prevent relapse and strongly support the concept that recruiting AML LIC from their low-cycling phenotype into proliferation might sensitize them towards, e.g., conventional chemotherapy. See supplemental Figure S1 and S2 for additional data.
Figure Legends
Figure 2 Low-cycling AML PDX cells are treatment resistant in vivo
A Experimental procedure; groups of mice were injected with CFSE labeled AML-PDX cells and treated with PBS (ctrl.) or a combination of 20 mg/kg DaunoXome® (DNX) on day 7 and 150 mg/kg cytarabine (Ara-C) on days 7 to 9; PDX cells were re-isolated from murine bone marrow on day 10 and analyzed as described in Figure 1B .
B
Tumor load was monitored by in vivo imaging in AML-393. re-transplanted into first recipient mice. Ten days after injection, cells were reisolated and sorted into LRC and non-LRC (nLRC) using the gates as described in Figure 1B and re-injected into secondary recipient mice.
Secondary recipient mice receiving either 300 LRC or 300 non-LRC (n=5)
were monitored by in vivo imaging.
C LRC and non-LRC were re-injected into secondary recipient mice (n=38) in limiting dilutions at numbers indicated in Table S3 . Positive engraftment of 
Supplemental Methods
Patients' acute myeloid leukemia (AML) cells
Lentiviral transduction of AML PDX cells and enrichment of transgenic cells
In vitro culture, lentiviral constructs, transduction, and sorting of transgenic PDX cells were performed as described previously. (3) In the study presented here, cells were transduced with a construct expressing enhanced firefly luciferase and mCherry in equimolar amounts (pCDH-EF1a-eFFly-mCherry, available via Addgene #104833).
Initial lentiviral transduction efficiencies were between 1% and 44% (AML-346 30%, AML-372 1%, AML-388 2%, AML-393 12%, AML-491 11%, AML-579 1%, AML-661 44%). PDX cells were sorted using a FACSAria III (BD Biosciences, Heidelberg, Germany) to reach a purity of more than 95% of mCherry + cells. As control, three AML PDX samples without transgenic expression of firefly luciferase and mCherry were applied (AML-356, AML-358, AML-538).
Bioluminescence in vivo imaging (BLI)
BLI and quantification of tumor burden was performed as described previously.(3, 5)
Labeling of PDX cells with carboxyfluorescein succinimidyl ester (CFSE)
Labeling of PDX cells with CFSE was performed as described previously. 
RNA sequencing and data analysis
Library Preparation of RNA-Seq: 1,000 and 2,000 cells of each individual sample were sorted and lysed in RLT Plus (Qiagen) supplemented with 1% 2-Mercaptoethanol (Sigma Aldrich) and stored at -80°C until processing. A modified SCRB-seq protocol (6, 7) was used for library preparation. Briefly, proteins in the lysate were digested by Proteinase K (Ambion), RNA was cleaned up using SPRI beads (GE, 22% PEG). In order to remove isolated DNA, samples were treated with DNase I for 15 min at RT. cDNA was generated by oligo-dT primers containing well specific (sample specific) barcodes and unique molecular identifiers (UMIs).
Unincorporated barcode primers were digested using Exonuclease I (Thermo Fisher). cDNA was pre-amplified using KAPA HiFi HotStart polymerase (Roche) and
pooled before Nextera libraries were constructed from 0.8 ng of pre-amplified cleaned up cDNA using Nextera XT Kit (Illumina). 3' ends were enriched with a custom P5 primer (P5NEXTPT5, IDT) and libraries were size selected using 2% E-Gel Agarose EX Gels (Life Technologies), cut out in the range of 300-800 bp, and extracted using the Monarch DNA Gel Extraction Kit (New England Biolabs) according to manufacturer's recommendations.
Sequencing: Libraries were paired-end sequenced on a rapid flow cell (1.5 lanes, ~208*10 6 reads in total) of an Illumina HiSeq 1500 instrument. Sixteen bases were sequenced within the first read to obtain cellular and molecular barcodes, and 50 bases were sequenced in the second read into the cDNA fragment. An additional eight bases were sequenced to obtain the i7 barcode.
Data processing and differential gene expression and pathway analysis: All raw fastq data was demultiplexed using deML (8) and further processed with zUMIs (9).
Mapping was performed using STAR 2.6.0a (10) against the concatenated human (hg38) and mouse genome (mm10). Gene annotations were obtained from Ensembl (GRCh38.84/GRCm38.75). Samples were identified via the cellular barcode, with initial phred score filtering allowing one base below 20. UMI phred filtering allowed one bases below phred 20. Differential gene expression of LRC and nLRC was calculated using the DESeq2 package following recommended workflows. (11) Pathway analysis using the MSigDB Collection "hallmark of cancer" and "KEGG" (v7.0) was conducted using default setting. (12, 13) Sequencing data are available at the NCBI Gene Expression Omnibus (GEO accession number: GSE141627).
In vivo treatment trials
AML PDX cells were injected into groups of mice (10 7 CFSE + PDX cells per mouse).
Seven days after cell injection, mice were treated with a combination of Cytarabine (150 mg/kg dissolved in PBS, i.p.) on days seven, eight, and nine, and one dose of DaunoXome (20 mg/kg i.v.) on day seven (see scheme in Figure 2A) . Body weight was measured daily. Tumor burden was monitored on days seven and ten by BLI. At day ten, mice were sacrificed, BM was collected, and AML PDX cells were isolated and analyzed for CFSE label retention as described above.
Analysis of plasticity of LRC and non-LRC
AML PDX cells were isolated from a first donor mouse, labeled with CFSE and transplanted into first recipient mice as described above. Ten (AML-393) or 15 (AML-491) days after injection, AML PDX cells were re-isolated and purely sorted into LRC and non-LRC fractions as described above (see also scheme in Figures 3 and S4) .
Limiting dilutions of sorted cells were re-injected into secondary recipient mice (between 30 and 3000 cells per mouse, see Table S3 ). To determine if highly proliferative cells convert into low-cycling cells, non-LRC from a primary recipient mouse were isolated at day 20 (AML-393) or 21 (AML-491), sorted, re-labeled with CFSE, and re-injected into secondary recipient mice (3.6*10 6 CFSE + AML-393 non-LRC, n=8, or 1.9*10 6 CFSE + AML-491 non-LRC, n=5). Cells were re-isolated at different time points after injection, distribution of LRC and non-LRC was analyzed, and compared to the distribution within first recipient mice.
For this analysis, many cells are needed for the re-injection into secondary recipient mice. The minute numbers of LRC that can be re-isolated after ten days from first recipient mice cannot be enriched from secondary recipient mice after re-transplantation; therefore, it is technically unfeasible to perform this analysis with the LRC fraction of cells.
Analysis of CD34 and CD38 immunophenotype
AML PDX cells were isolated from a first donor mouse, labeled with CFSE and 10 7 cells were transplanted into first recipients. Ten (AML-393) or 14 (AML-491) days after injection, AML PDX cells were re-isolated as described above. After Mouse Cell Figure 3B and S4B) * LRC and non-LRC from first recipient mice were sorted and were transplanted into secondary recipient mice in limiting dilutions at numbers indicated; bioluminescence in vivo imaging, blood measurement or bone marrow FACS staining was performed to determine engraftment; LIC frequency was calculated using the ELDA software; 95% confidence interval (CI).
Figure S1
AML PDX cells display heterogeneity regarding in vivo proliferation, homing and LIC frequency (related to Figure 1) .
A In vivo doubling times were calculated out of growth curves measured as in Figures  1D and S2. B Passaging times from injection until overt leukemia, 5x10 5 to 5x10 6 AML PDX cells were injected per mouse; mean +/-SD of at least 4 and up to 100 mice per sample is depicted. dpi=days post injection.
C Number of AML PDX cells homing to the BM was determined 2 or 3 days following injection of 10 7 cells; mean +/-SD of at least 3 mice is shown.
D Bulk cells from different AML samples were transplanted into recipient mice in limiting dilutions at numbers indicated in Table S2 . LIC frequency was calculated using the ELDA software and mean +/-95%CI is depicted. Experiments were performed and data depicted identically as in Figure 3; A Experimental procedure; AML-491 PDX cells were isolated from advanced disease donor mice (n=2 in two independent experiments), labeled with CFSE, and retransplanted into first recipient mice. Fifteen days after injection, cells were reisolated and sorted into LRC and non-LRC (nLRC) using the gates as described in Figure 1B and re-injected into secondary recipient mice.
B Secondary recipient mice receiving either 1200 LRC or 1200 non-LRC (n=4) were monitored by in vivo imaging.
C LRC and non-LRC were re-injected into secondary recipient mice (n=11) in limiting dilutions at numbers as indicated in Table S3 . Positive engraftment of PDX cells was determined by in vivo imaging and/or flow cytometry. LIC frequency was calculated using the ELDA software and is depicted +/-95% confidence interval. No statistically significant difference between LIC frequency of LRC and non-LRC was found according to chi-square test (p=0.95).
D Experimental procedure; from first recipient mice (n=2 in 2 independent experiments) harboring CFSE stained cells, non-LRC were isolated at day 21, restained with CFSE and 1.9*10 6 cells injected into secondary recipients; (n=5); Cells were re-isolated 14, 15 and 21 days later and LRC were quantified using gates as described in Figure 1B . The experiment is technically unfeasible for LRC as the high number of cells needed cannot be generated.
E,F Representative dot plots (E) and quantification (F) of the percentage of LRC among all PDX cells isolated from secondary recipients is displayed (green squares). LRC of first recipient mice as determined in Figure S2A are shown for comparison (dots in light green). Table S3 for additional data.
See supplemental
Figure S4
AML PDX cells display reversible growth behavior, independently from stemness potential (related to Figure 3 , additional sample AML-491).
Figure S5
Low-cycling cells are not enriched in immature cells.
AML-393 and AML-491 PDX cells were isolated from full-blown donor mice, labeled with CFSE, and 10 7 cells were re-transplanted into first recipient mice. Ten (AML-393; n=4) or fourteen (AML-491; n=6) days after injection, cells were re-isolated, stained with CD34 and CD38 antibodies and percentage of CD34 and CD38 positive cells within the LRC and non-LRC compartment were analyzed by flow cytometry.
A representative dot plots B percentage of CD34-positive and CD38-negative cells within the LRC and non-LRC compartment is depicted as mean+/-SD. Each dot/square represents one mouse;
